Vimpat lacosamide regulatory update

FDA approved an sNDA for Vimpat lacosamide as monotherapy to treat partial-onset seizures in adult epileptics. Vimpat is already approved as adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy in at least 43 countries, including the U.S. and those of the EU. FDA also approved a new single loading dose option for all formulations of Vimpat, allowing for the initiation of Vimpat as a single loading dose of 200 mg, followed about 12 hours later by a 100 mg twice-daily dose. ...